University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ

Authored Items

Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Eribulin mesylate (EM) is a microtubule inhibitor shown to improve survival in patients with metastatic breast cancer (MBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. A common grade 3/4 toxicity of EM is neutropenia which may result in dose adjustments and dose delays. To minimze neutropenic complications, granulocyte colony-stimulating factor (GCSF or GMCSF) may be utilized, as well as dose modifications or treatment discontinuation. [ Read More ]